

MEETING ABSTRACT

Open Access

# Post exposition to etoricoxib in patients with negative oral drug provocation tests

Thais Sterza<sup>1\*</sup>, Pedro HR Fernandes<sup>2</sup>, Cristiane Momoi<sup>2</sup>, Luis Felipe Ensina<sup>2</sup>, Inês Cristina Camelo Nunes<sup>2</sup>, Dirceu Solé<sup>2</sup>

From 3rd WAO International Scientific Conference (WISC) 2014  
Rio de Janeiro, Brazil. 6-9 December 2014

## Background

The etoricoxib can be used as a therapeutical alternative to patients with hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs). The aim of this study was to evaluate the use of etoricoxib in daily life of patients with negative oral drug provocation tests (DPT).

## Methods

Patients with hypersensitivity to NSAIDs that performed a DPT with etoricoxibe between january/2013 and june/2014 were contacted by phone and asked about posterior etoricoxib drug usage and the occurrence of reactions. Those who had not used again were asked the reasons for not using.

## Results

Forty-one patients were tested, all with negative results. Thirty seven of them (90%) were contacted and 28 (76%) remembered the tested drug's name. Twelve of them (32%) had used the drug again without any reaction. Twenty five patients were not re-exposed: 18 did not need, 4 were afraid of a new reaction and 3 used another alternative. Of the 4 patients who were afraid to use the drug again, 3 of them had presented anaphylaxis symptoms with other NSAIDs.

## Conclusions

Most of the patients exposed to etoricoxib DPT haven't been exposed again to the drug. Of those who were afraid to use the drug again, most had a severe reaction history to NSAIDs.

## Authors' details

<sup>1</sup>Emescam College of Health Sciences, Brazil. <sup>2</sup>Federal University of São Paulo, Brazil.

Published: 8 April 2015

doi:10.1186/1939-4551-8-S1-A186

**Cite this article as:** Sterza et al.: Post exposition to etoricoxib in patients with negative oral drug provocation tests. *World Allergy Organization Journal* 2015 **8**(Suppl 1):A186.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Emescam College of Health Sciences, Brazil  
Full list of author information is available at the end of the article